VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue1,702,1771,032,336580,415
Cost of Revenue210,460124,51260,987
Gross Profit1,491,717907,824519,428
Operating Expenses
Research Development1,047,690995,922855,506
Selling General and Administrative432,829376,575305,409
Non Recurring1,2622,20650,925
Total Operating Expenses---
Operating Income or Loss9,936-466,879-692,412
Income from Continuing Operations
Total Other Income/Expenses Net4,130-6,71530,400
Earnings Before Interest and Taxes14,066-473,594-662,012
Interest Expense81,43284,20672,863
Income Before Tax-67,366-557,800-734,875
Income Tax Expense16,66530,3816,958
Minority Interest181,609153,66121,177
Net Income From Continuing Ops-84,031-588,181-741,833
Non-recurring Events
Discontinued Operations---912
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-112,052-556,334-738,555
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-112,052-556,334-738,555